02 · Clinical Findings
Triple-Target Incretin Drug Kills Knee Osteoarthritis Pain in Obesity
In a 68 week trial of 445 patients, weekly retatrutide injections cut WOMAC pain scores by over 4.4 points while helping participants lose more than a quarter of their body weight.

In the 68-week TRIUMPH-4 trial of 445 patients with obesity and knee osteoarthritis, weekly retatrutide injections cut WOMAC pain scores by over 4.4 points versus 2.43 with placebo.
Targeting GLP-1, GIP, and glucagon receptors, the drug helped participants shed over a quarter of their body weight despite substantial baseline joint damage.
Authors in the New England Journal of Medicine noted that lighter knee loads and lower adipose inflammation may drive the relief, while calling for further study.
Read the full story at MedPage Today ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit

At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes

Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years

Continue reading · Clinical FindingsPeptide News / Clinical FindingsGLP-1s confer better glycemic, CV outcomes than metforminHealio Endocrinology · Nov 6, 2026 · scroll to read